From the Guidelines
Nerve growth factor (NGF) is the most promising peptide for nerve regeneration, as it has been shown to reduce allodynia and hyperalgesia through reduction of reactive astrocytosis and glial modulation, and its use has been associated with the improvement of symptoms of neuropathic corneal pain (NCP) 1. When considering peptides for nerve regeneration, several options are available, including BPC-157, TB-500, and Cerebrolysin. However, based on the most recent and highest quality study, NGF is the most effective peptide for promoting nerve growth and reducing symptoms of NCP.
- BPC-157 is typically administered at 250-500mcg once or twice daily via subcutaneous injection for 4-8 weeks, promoting nerve growth factor expression and accelerating peripheral nerve healing.
- TB-500 (Thymosin Beta-4) is usually dosed at 2-2.5mg twice weekly for 4-6 weeks, enhancing cell migration and reducing inflammation in damaged neural tissue.
- Cerebrolysin, administered at 5-30ml daily via intramuscular injection or IV for 10-20 days, contains neurotrophic factors that support neuronal survival and axonal growth.
- Autologous serum tears (AST) have also been shown to be effective in promoting nerve regeneration and reducing symptoms of NCP, with a recommended dosage of 20% AST 8x/daily until significant relief/resolution of symptoms is achieved, followed by a slow taper 1. It is essential to consult with a healthcare provider before beginning any peptide therapy, as administration routes, proper storage, and potential side effects require professional guidance.
From the Research
Peptides for Nerve Regeneration
- Acetyl-L-carnitine (ALCAR) is a peptide that has been shown to enhance nerve regeneration in various studies 2, 3, 4, 5, 6
- ALCAR has been found to increase the number of regenerating nerve fibers, improve the quality of regeneration, and enhance target organ reinnervation 3, 4
- Studies have demonstrated that ALCAR treatment can improve nerve conduction velocities, vibration perception, and pain symptoms in patients with peripheral neuropathy 5, 6
- ALCAR has been shown to be safe and effective in clinical trials, with a good safety profile and significant pain reduction compared to placebo 5, 6
Mechanism of Action
- ALCAR facilitates the transport of fatty acids, which is essential for mitochondrial function and neuronal survival 2
- ALCAR has been found to prevent neuronal loss and promote nerve regeneration by increasing aerobic capacity and preventing oxidative stress 3, 4
Clinical Applications
- ALCAR has been used to treat various forms of peripheral neuropathy, including diabetic neuropathy, antiretroviral toxic neuropathy, and chemotherapy-induced peripheral neuropathy 5, 6
- ALCAR may be a useful adjuvant treatment to enhance nerve regeneration and improve functional outcomes in patients with peripheral nerve injury or compression neuropathy 2, 3, 4